22nd March 2023

Pharmanovia enters into exclusive licensing agreement with Aeterna Zentaris

FOR TRADE AND BUSINESS MEDIA ONLY

More information
22nd February 2023

Pharmanovia enters in-licensing agreement with Axsome Therapeutics

FOR TRADE AND BUSINESS MEDIA ONLY

More information
25th January 2023

Pharmanovia makes leadership hires in China

FOR TRADE AND BUSINESS MEDIA ONLY

More information
13th October 2022

Pharmanovia bolsters Scientific Affairs team with new hires

Dr Claire Ives (Senior MSL Director) and Dr Fernando Osorio (MSL Director) will together head Pharmanovia’s influential Medical...

More information
28th September 2022

Pharmanovia enters exclusive licensing collaboration for Diazepam Buccal Film

For Trade and Medical Media ONLY PHARMANOVIA EXCLUSIVELY LICENCES RIGHTS FOR A NOVEL WAY OF TREATING...

More information
11th July 2022

DKSH and Pharmanovia partner to respond to therapeutic needs in Southeast Asia

DKSH will support life cycle management company Pharmanovia in its mission to bring important medication to...

More information
4th July 2022

Pharmanovia expands its footprint in China with the acquisition of Rocaltrol® from Roche

Pharmanovia has acquired the commercial rights in China for Rocaltrol® (calcitriol) Roche. Pharmanovia obtained the...

More information
5th April 2022

Life cycle management company Pharmanovia launches its inaugural sustainability report

The report celebrates the firm’s diversity and sets out ambitious environmental and sustainability targets London, UK...

More information
29th March 2022

Pharmanovia announces departure of Chief Corporate Development Officer Alastair Hay

LONDON – Alastair Hay is leaving his position as Chief Corporate Development Officer at the global...

More information

For all media enquiries please contact: communications@pharmanovia.com